Modeling the adenoma and serrated pathway to colorectal cancer (ASCCA)

Risk Analysis

Volumn 34, Issue 5, 2014, Pages 889-910

  Greuter, Marjolein J E ^a   Xu, Xiang Ming ^b,c   Lew, Jie Bin ^b,c   Dekker, Evelien ^d   Kuipers, Ernst J ^e   Canfell, Karen ^b,c   Meijer, Gerrit A ^a   Coupé, Veerle M H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CANCER RESEARCH DIVISION   (Australia)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; Colorectal lesions; Health economic modeling; Screening

Indexed keywords

CALIBRATION; DISEASES; ENDOSCOPY; SCREENING; SOFTWARE TESTING;

CALIBRATION PROCEDURE; COLORECTAL CANCER; COLORECTAL CANCERS (CRC); COLORECTAL LESIONS; HEALTH ECONOMICS; SCREENING MODELS; SCREENING PROGRAMS; SCREENING STRATEGY;

TUMORS;

CALIBRATION; CANCER; DISEASE INCIDENCE; HEALTH RISK;

ADENOMA; COLONOSCOPY; COLORECTAL TUMOR; HUMAN; PATHOLOGY; THEORETICAL MODEL;

ADENOMA; COLONOSCOPY; COLORECTAL NEOPLASMS; HUMANS; MODELS, THEORETICAL;

EID: 84900556250     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/risa.12137     Document Type: Article

References (68)

1. World Health Organization: International Agency for Research on Cancer. GLOBOCAN 2008. Available at: http://globocan.iarc.fr/. Accessed on September 16, 2012.
2. European Cancer Observatory. Cancer screening: Colon and rectum. Available at: http://eu-cancer.iarc.fr, Accessed on September 20, 2012.
3. Gezondheidsraad. Bevolkingsonderzoek naar darmkanker. Den Haag: Gezondheidsraad. 2009; Publicatienr. 2009.13.
4. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: A decision analysis for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2008; 149(9):659-669.
5. Hassan C, Benamouzig R, Spada C, Ponchon T, Zullo A, Saurin JC, Costamagna G. Cost effectiveness and projected national impact of colorectal cancer screening in France. Endoscopy, 2011; 43(9):780-793.
6. Parkin DM, Tappenden P, Olsen AH, Patnick J, Sasieni P. Predicting the impact of the screening programme for colorectal cancer in the UK. Journal of Medical Screening, 2008; 15(4):163-174.
7. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Computers & Biomedical Research, 1999; 32(1):13-33.
8. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. Journal of the American Medical Association, 2000; 284(15):1954-1961.
9. Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J. Option appraisal of population-based colorectal cancer screening programmes in England. Gut, 2007; 56(5):677-684.
10. Eddy DM, Nugent FW, Eddy JF, Coller J, Gilbertsen V, Gottlieb LS, Rice R, Sherlock P, Winawer S. Screening for colorectal cancer in a high-risk population. Results of a mathematical model. Gastroenterology, 1987; 92(3):682-692.
11. Neilson AR, Whynes DK. Cost-effectiveness of screening for colorectal cancer: A simulation model. IMA Journal of Mathematics Applied in Medicine and Biology, 1995; 12(3-4):355-367.
12. Ness RM, Holmes AM, Klein R, Dittus R. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. American Journal of Gastroenterology, 2000; 95(7):1800-1811.
13. Rutter CM, Savarino JE. An evidence-based microsimulation model for colorectal cancer: Validation and application. Cancer Epidemiology, Biomarkers, & Prevention, 2010; 19(8):1992-2002.
14. Howard DH, Tangka FK, Seeff LC, Richardson LC, Ekwueme DU. The impact of detection and treatment on lifetime medical costs for patients with precancerous polyps and colorectal cancer. Health Economics, 2009; 18(12):1381-1393.
15. Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ. Colorectal cancer screening for average-risk North Americans: An economic evaluation. PLoS Medicine, 2010; 7(11):e1000370.
16. Morson BC. Evolution of cancer of the colon and rectum. Cancer, 1974; 34(3):845-849.
17. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer, 1975; 36(6):2251-2270.
18. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology, 2010; 138(6):2088-2100.
19. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology, 2007; 50(1):113-130.
20. Burke CA, Snover DC. Editorial: Sessile serrated adenomas and their pit patterns: We must first see the forest through the trees. American Journal of Gastroenterology, 2012; 107(3):470-472.
21. O'Brien MJ. Hyperplastic and serrated polyps of the colorectum. Gastroenterology Clinics of North America, 2007; 36(4):947-968.
22. Snover DC. Update on the serrated pathway to colorectal carcinoma. Human Pathology, 2011; 42(1):1-10.
23. Jass JR. Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nature Clinical Practice Oncology, 2005; 2(8):398-405.
24. Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: Current concepts and challenges. Histopathology, 2013; 62(3):367-386.
25. Waldock A, Ellis IO, Armitage NC, Turner DR, Hardcastle JD. Histopathological assessment of bleeding from polyps of the colon and rectum. Journal of Clinical Pathology, 1989; 42(4):378-382.
26. East JE, Saunders BP, Jass JR. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: Classification, molecular genetics, natural history, and clinical management. Gastroenterology Clinics of North America, 2008; 37(1):25-46.
27. Sweetser S, Smyrk TC, Sinicrope FA. Serrated colon polyps as precursors to colorectal cancer. Clinical Gastroenterology and Hepatology, 2013; 11(7):760-767.
28. Stoop EM, de Haan MC, de Wijkerslooth TR, Bossuyt PM, van Ballegooijen M, Nio CY, van de Vijver MJ, Biermann K, Thomeer M, van Leerdam ME, Fockens P, Stoker J, Kuipers EJ, Dekker E. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: A randomised controlled trial. Lancet Oncology, 2012; 13(1):55-64.
29. Boost library. Available at: http://www.boost.org./, Accessed on February 10, 2012.
30. Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM. Adenomatous lesions of the large bowel: An autopsy survey. Cancer, 1979; 43(5):1847-1857.
31. Vatn MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: An autopsy study. Cancer, 1982; 49(4):819-825.
32. Bombi JA. Polyps of the colon in Barcelona, Spain. An autopsy study. Cancer, 1988; 61(7):1472-1476.
33. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. New England Journal of Medicine, 1988; 319(9):525-532.
34. Risio M. The natural history of adenomas. Best Practice & Research Clinical Gastroenterology, 2010; 24(3):271-280.
35. Haug U, Knudsen AB, Brenner H, Kuntz KM. Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Review of Molecular Diagnostics, 2011; 11(6):605-616.
36. Winawer SJ, Zauber AG. The advanced adenoma as the primary target of screening. Gastrointestinal Endoscopy Clinics of North America, 2002; 12(1):1-9.
37. Bersentes K, Fennerty MB, Sampliner RE, Garewal HS. Lack of spontaneous regression of tubular adenomas in two years of follow-up. American Journal of Gastroenterology, 1997; 92(7):1117-1120.
38. Hoff G, Foerster A, Vatn MH, Sauar J, Larsen S. Epidemiology of polyps in the rectum and colon. Recovery and evaluation of unresected polyps 2 years after detection. Scandinavian Journal of Gastroenterology, 1986; 21(7):853-862.
39. Hofstad B, Vatn MH, Andersen SN, Huitfeldt HS, Rognum T, Larsen S, Osnes M. Growth of colorectal polyps: Redetection and evaluation of unresected polyps for a period of three years. Gut, 1996; 39(3):449-456.
40. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, Ackroyd F, Shike M, Kurtz RC, Hornsby-Lewis L, Gerdes H, Stewart ET, and the National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. New England Journal of Medicine, 1993; 329(27):1977-1981.
41. Loeve F, Boer R, Zauber AG, Van Ballegooijen M, Van Oortmarssen GJ, Winawer SJ, Habbema JD. National Polyp Study data: Evidence for regression of adenomas. International Journal of Cancer, 2004; 111(4):633-639.
42. Kudo Se, Lambert R, Allen JI, Fujii H, Fujii T, Kashida H, Masuda T, Mori M, Saito H, Shimoda T, Tanaka S, Watanabe H, Sung JJ, Feld AD, Inadomi JM, O'Brien MJ, Lieberman DA, Ransohoff DF, Soetikno RM, Triadafilopoulos G, Zauber A, Teixeira CR, Rey JF, Jaramillo E, Rubio CA, Van Gossum A, Jung M, Viet M, Jass JR, Hurlstone PD. Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointestinal Endoscopy, 2008; 68(4):S3-S47.
43. Noffsinger AE. Serrated polyps and colorectal cancer: New pathway to malignancy. Annual Review of Pathology, 2009; 4:343-364.
44. Higuchi T, Sugihara K, Jass JR. Demographic and pathological characteristics of serrated polyps of colorectum. Histopathology, 2005; 47(1):32-40.
45. Rutter CM, Yu O, Miglioretti DL. A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts. Statistics in Medicine, 2007; 26(1):98-109.
46. IKNL. Cijfers over kanker, 2011. Available from: http://www.cijfersoverkanker.nl./, Accessed on February 6, 2012.
47. De Wijkerslooth TR, de Haan MC, Stoop EM, Deutekom M, Fockens P, Bossuyt PMM, Tomeer M, van Ballegooijen M, Essink-Bot ML, van Leerdam ME, Kuipers EJ, Dekker E, Stoker J. Study protocol: Population screening for colorectal cancer by colonoscopy or CT colonography: A randomized controlled trial. BMC Gastroenterology, 2010; 10:47.
48. Visser O, van Leeuwen FE. Stage-specific survival of epithelial cancers in North-Holland/Flevoland, the Netherlands. European Journal of Cancer, 2005; 41(15):2321-2330.
49. Brenner H, Altenhofen L, Katalinic A, Lansdorp-Vogelaar I, Hoffmeister M. Sojourn time of preclinical colorectal cancer by sex and age: Estimates from the German national screening colonoscopy database. American Journal of Epidemiology, 2011; 174(10):1140-1146.
50. Central Bureau for Statistics. 2012. Available from: http://www.cbs.nl, Accessed on March 2, 2012.
51. Van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: A systematic review. American Journal of Gastroenterology, 2006; 101(2):343-350.
52. Ahn SB, Han DS, Bae JH, Byun TJ, Kim JP, Eun CS. The miss rate for colorectal adenoma determined by quality-adjusted, back-to-back colonoscopies. Gut and Liver, 2012; 6(1):64-70.
53. Ee HC, Semmens JB, Hoffman NE. Complete colonoscopy rarely misses cancer. Gastrointestinal Endoscopy, 2002; 55(2):167-171.
54. Lüning TH, Keemers-Gels ME, Barendregt WB, Tan ACIT, Rosman C. Colonoscopic perforations: A review of 30, 366 patients. Surgical Endoscopy, 2007; 21(6):994-997.
55. Panteris V, Haringsma J, Kuipers EJ. Colonoscopy perforation rate, mechanisms and outcome: From diagnostic to therapeutic colonoscopy. Endoscopy, 2009; 41(11):941-951.
56. Van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology, 2008; 135(1):82-90.
57. Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink JCIY, van der Togt AC, Kuipers EJ, Habbema JD, van Leerdam ME. Screening for colorectal cancer: Random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. British Journal of Cancer, 2009; 100(7):1103-1110.
58. Nederlandse Vereniging van Maag-Darm-Leverartsen. Follow-up na poliepectomie, 2002.
59. Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JD. Endoscopic colorectal cancer screening: A cost-saving analysis. Journal of the National Cancer Institute, 2000; 92(7):557-563.
60. Vijan S, Hwang EW, Hofer TP, Hayward RA. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. American Journal of Medicine, 2001; 111(8):593-601.
61. Muto T, Nagawa H, Watanabe T, Masaki T, Sawada T. Colorectal carcinogenesis: Historical review. Diseases of the Colon and Rectum, 1997; 40(10 Suppl):S80-S85.
62. Goede SL, van Roon AHC, Reijerink JCIY, van Vuuren AJ, Lansdorp-Vogelaar I, Habbema JD, van Ballegooijen M. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut, 2013; 62(5):727-734.
63. Wilschut JA, Hol L, Dekker E, Jansen JB, Van Leerdam ME, Lansdorp-Vogelaar I, Kuipers EJ, Habbema JD, van Ballegooijen M. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology, 2011; 141(5):1648-1655.e1.
64. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. British Journal of Cancer, 2004; 91(12):1983-1989.
65. Meza R, Jeon J, Renehan AG, Luebeck EG. Colorectal cancer incidence trends in the United States and United Kingdom: Evidence of right- to left-sided biological gradients with implications for screening. Cancer Research, 2010; 70(13):5419-5429.
66. Pickhardt PJ, Kim DH, Pooler BD, Hinshaw JL, Barlow D, Jensen D, Reichelderfer M, Cash BD. Assessment of volumetric growth rates of small colorectal polyps with CT colonography: A longitudinal study of natural history. Lancet Oncology, 2013; 14(8):711-720.
67. Brenner H, Altenhofen L, Stock C, Hoffmeister M. Natural history of colorectal adenomas: Birth cohort analysis among 3.6 million participants of screening colonoscopy. Cancer Epidemiology, Biomarkers, & Prevention, 2013; 22(6):1043-1051.
68. Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. American Journal of Gastroenterology 2010; 105(11):2457-2464.